News. Analysis. Insight.™ - 100 Years of Journalistic Excellence

Nanosphere, Inc. develops, manufactures, and markets a molecular diagnostics platform, the Verigene System, that enables genomic and protein testing on a single platform. Its proprietary nanoparticle technology provides the ability to run multiple tests at the same time on the same sample, and enables the development of various test assays to be performed on a single platform. The company is developing diagnostic tests for a range of medical conditions, including cancer, neurodegenerative, cardiovascular, and infectious diseases, as well as pharmaco-genomics or tests for personalized medicine. It is also developing other genomic assays, including tests for cystic fibrosis and a range of infectious diseases. In addition, the company has a program to develop protein tests based on established biomarkers and to validate new biomarkers, in which its ultra-sensitive protein detection technology enables earlier detection of various diseases. Nanosphere was founded in 1998 and is headquartered in Northbrook, Illinois.

Industry	Medical Instruments & Supplies
Sector	Healthcare
# of Employees	113
Shares Outstanding	27.6M
Market Cap	173.6M
Enterprise Value	-

52-Week High	$8.61
52-Week Low	$2.71
P/E Ratio	-4.05
EPS	-$1.55/shr
Dividend	-
Yield	-

William Moffitt III

C.E.O., Pres.

William Cork

C.T.O., V.P. - Research and Development

Michael McGarrity

Chief Marketing Officer

Gregory W. Shipp

Chief Medical Officer, V.P.

Chad Mirkin

Co-Founder, Dir.

Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes.
All other data is delayed at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Real Time Stock News provided by MarketMinute.com
Stock Analysis provided by SocialPicks Conference calls info supplied by OpenCompany
Fundamental data supplied by Mergent, Inc.
Stock quote data supplied by Telekurs